• Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off
Reading...
Front

How to study your flashcards.

Right/Left arrow keys: Navigate between flashcards.right arrow keyleft arrow key

Up/Down arrow keys: Flip the card between the front and back.down keyup key

H key: Show hint (3rd side).h key

A key: Read text to speech.a key

image

Play button

image

Play button

image

Progress

1/33

Click to flip

33 Cards in this Set

  • Front
  • Back
phytonadione (vitamin K1)
overcomes warfarin inhibiion of hepatic epoxide reductase. given orally or parenterally
heparin sodium
combines w/ antithrombin III and inhibits hemostasis by nonselective inactivation of factors IIa, IXa, Xa, XIa and XIIIa. higher incidence of HIT than LMWH
protamine
inactivates heparin by forming a stable 1:1 complex.
enoxaparin
LMWH: combines w/ antithrombin III and inhibits secondary hemostasis via selective inactivation of factor Xa and IIa(thrombin - less) SQ
dalteparin
LMWH: combines w/ antithrombin III and inhibits secondary hemostasis via selective inactivation of factor Xa and IIa(thrombin - less) SQ
tinzaparin
LMWH: combines w/ antithrombin III and inhibits secondary hemostasis via selective inactivation of factor Xa and IIa(thrombin - less) SQ
lepirudin
direct thrombin inhibitor: binds directly to thrombin and inhibits coagulation. essentially irreversible
bivalirudin
direct thrombin inhibitor: binds directly to thrombin and inhibits coagulation. reversible.
desirudin
direct thrombin inhibitor: binds directly to thrombin and inhibits coagulation
argatroban
direct thrombin inhibitor: binds directly to thrombin (active site ONLY) and inhibits coagulation. reversible
dabigatran
direct thrombin inhibitor: binds directly to thrombin and inhibits coagulation. only oral direct thrombin inhibitor. reversible
drotecogin alfa/ recombinant activated protein C
proteolytically inactivates factors Va and VIIIa. WITHDRAWN FROM MARKET
fondaparinux
indirect factor Xa inhibitor: combines w/ antithrombin III and inhibits hemostasis via highly selective inactivation of factor Xa. no monitoring.
rivaroxaban
direct factor Xa inhibitor: combines directly w/ free and clot bound factor Xa. oral. high bioavailability
apixaban
direct factor Xa inhibitor: combines directly w/ free and clot bound factor Xa. IN TRIALS STILL. oral.
warfarin
vitamin K antagonist: inhibits hepatic epoxide reductase required for synthesis of biologically active coag factors II, VII, IX, X and anticoagulant proteins C and S. oral. requires monitoring. avoid in pregnancy
streptokinase
proteolytically activates plasminogen to form plasmin which digests fibrin to fibrin degradation products. can cause allergic reactions and doesn't bind fibrin.
alteplase
proteolytically activates plasminogen to form plasmin which digests fibrin to fibrin degradation products.
reteplase
proteolytically activates plasminogen to form plasmin which digests fibrin to fibrin degradation products. longer halflife than alteplase
tenecteplase
proteolytically activates plasminogen to form plasmin which digests fibrin to fibrin degradation products. higher affinity and longer halflife than alteplase
aminocaproic acid
lysine analog: binds and inhibits plasminogen and plasmin.
tranexamic acid
lysine analog: binds and inhibits plasminogen and plasmin
aprotinin
serine protease inhibitor: inhibits serine proteases including plasmin, t-PA, and thrombin. WITHDRAWN FROM THE MARKET.
aspirin
COX inhibitor: inhibits platelet cyclooxygenase blocking thromboxane A2 production
dipyridamole
cAMP elevating agent: inhibits reuptake of adenosine leading to A2 receptor mediated stimulation of adenylate cyclase.
cilostazol
cAMP elevating agent: inhibts cAMP phosphodiesterase (PDE III) used for intermittent claudication. contraindicated in heart failure. reversible inhibition
ticlodipine
covalently modifies platelet ADP receptor (2PY12 inhibitor) oral agents
clopidogrel
covalently modifies platelet ADP receptor (2PY12 inhibitor) oral agents. favored over ticlodipine
prasugrel
covalently modifies platelet ADP receptor (2PY12 inhibitor) oral agents. more potent than clopidogrel
ticagrelor
covalently modifies platelet ADP receptor (2PY12 inhibitor) oral agents
tirofiban
GP IIb/IIIa inhibitor: binds to platelet receptor GP IIB/IIIa and prevents binding of fibrinogen and other adhesive ligands. nonpeptide tyrosine analog
abciximab
GP IIb/IIIa inhibitor: binds to platelet receptor GP IIB/IIIa and prevents binding of fibrinogen and other adhesive ligands. chimeric Fab fragment
eptifibatide
GP IIb/IIIa inhibitor: binds to platelet receptor GP IIB/IIIa and prevents binding of fibrinogen and other adhesive ligands. cyclic peptide.